The Science of Targeted Biologics: How Anti-FGF23 Injections Normalize Growth Plates

Fibroblast growth factor 23 (FGF23) is a hormone critical for phosphate balance. In certain genetic conditions—most notably X-linked hypophosphatemia (XLH)—FGF23 levels become too high. Excess FGF23 drives phosphate loss through the kidneys, leading to weak, under-mineralized bones and disrupted growth plates in children. Traditional treatments often fall short, but targeted biologics—specifically anti-FGF23 monoclonal antibodies—are transforming care.

---

Understanding FGF23 and Growth Plate Physiology

1. Role of Phosphate in Bone Health

   • Phosphate is essential for bone mineralization and energy metabolism.
   • In growing children, adequate phosphate ensures the cartilage in growth plates turns into strong bone.

2. FGF23 Function

   • Produced by bone cells, FGF23 lowers blood phosphate by:
     • Reducing phosphate reabsorption in the kidneys
     • Decreasing active vitamin D levels
   • Normally, it prevents phosphate overload.

3. When FGF23 Goes Awry

   • In XLH and related disorders, mutations lead to continually elevated FGF23.
   • Consequences:
     • Chronic low serum phosphate (hypophosphatemia)
     • Rachitic deformities (bowed legs, short stature)
     • Growth plate abnormalities (widening, irregular mineralization)

---

Targeted Biologics: The Rise of Anti-FGF23 Therapy

Monoclonal antibodies are lab-designed proteins that bind specific targets. Anti-FGF23 antibodies neutralize excess FGF23, restoring phosphate balance and helping growth plates form healthy bone.

• Burosumab (KRN23) is the first FDA-approved anti-FGF23 antibody for XLH in children and adults.
• Mechanism of action:
  1. Binds circulating FGF23
  2. Blocks its interaction with kidney receptors
  3. Increases renal phosphate reabsorption
  4. Boosts active vitamin D production

---

Key Findings from FGF23 Monoclonal Antibody Clinical Trial Results Children

Clinical trials have rigorously evaluated safety and efficacy in pediatric XLH. Here’s what researchers have observed:

Phase 2 Studies

• Population: Children aged 5–12 with confirmed XLH
• Treatment: Burosumab every 2–4 weeks vs. conventional therapy (phosphate supplements + active vitamin D)
• Primary outcomes: Serum phosphate levels, rickets severity by radiographic scoring
• Results:
  • Serum Phosphate: Normalized in most treated children within 1 month
  • Radiographic Improvement: Significant reduction in rickets severity scores at 24 and 40 weeks
  • Growth Plate Morphology: Narrower, more regular zones on MRI assessments

Phase 3 Randomized Trials

• Population: 6–12-year-olds with moderate to severe XLH
• Design: Burosumab (0.8 mg/kg every 2 weeks) vs. placebo, then open-label extension
• Key endpoints at 64 weeks:
  • Rickets Severity Score (RSS): Mean reduction of 2.0 points vs. 0.5 in placebo
  • Walking Ability & Pain: Parents reported less leg pain and improved mobility
  • Growth Velocity: Modest increase (≈0.7 cm/year over baseline)
• Safety profile:
  • Common events: Injection-site reactions, headache, mild fever
  • Serious events: Rare; transient hyperphosphatemia in a few children, managed by dose adjustment

Long-Term Follow-Up

• Sustained benefits over 2–4 years:
  • Continued radiographic healing of rickets
  • Steady improvements in height Z-scores
  • No new safety signals; kidney ultrasounds show no nephrocalcinosis progression

---

Practical Considerations for Families and Clinicians

When considering anti-FGF23 therapy, keep the following in mind:

• Dosing & Administration

  • Subcutaneous injections every 2–4 weeks
  • Weight-based dosing guided by serum phosphate and clinical response

• Monitoring

  • Serum phosphate, calcium, and vitamin D levels before each dose
  • Periodic renal ultrasound to watch for nephrocalcinosis
  • Growth plate imaging if clinically indicated

• Potential Side Effects

  • Mild: Injection-site redness, headaches, fatigue
  • Less common: Transient hyperphosphatemia (high phosphate)
  • Rare: Hypersensitivity reactions—report any unusual rash or breathing issues immediately

• Contraindications & Cautions

  • Severe kidney impairment requires careful dose adjustments
  • Active infection or immune deficiencies—discuss risks with your doctor

---

Real-World Impact on Children’s Lives

Families participating in expanded access and post-approval registries have shared positive transformations:

• Reduced bone pain and fewer muscle cramps
• Better alignment of legs, enabling more active play
• Noticeable gains in height and self-confidence
• Decreased need for orthopedic surgeries and physical therapy

---

What This Means for You

If your child has:

• Persistent leg bowing, short stature, or delayed walking
• Chronic bone pain or muscle weakness
• A family history of XLH or phosphate-wasting disorders

It may be time to explore targeted biologics. Early intervention can lead to better outcomes, preserving growth plate health and quality of life.

You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify your child’s symptoms before speaking with a specialist.

---

Next Steps: Speak to a Doctor

This information is intended to help you understand how anti-FGF23 monoclonal antibodies work and what clinical trials in children have demonstrated. It’s not a substitute for professional medical advice.

If you suspect serious or life-threatening issues—such as severe bone deformities, uncontrollable pain, or signs of heart or kidney complications—please speak to a doctor immediately.

Always consult a pediatric endocrinologist or metabolic bone specialist before starting or changing any treatment plan. They can tailor therapy based on your child’s unique needs and monitor long-term safety.

---

By targeting the root cause—elevated FGF23—monoclonal antibodies offer a precision approach to normalize growth plates and support lifelong bone health. Ongoing research continues to refine dosing and expand our understanding of long-term benefits, bringing hope to children and families affected by phosphate-wasting disorders.